产品标题 产品货号 产品规格 厂家
Temozolomide - TMZ | NSC 362856 | SCH 52365 | CCRG 81045Axon 2326 CAS [85622-93-1] MF C6H6N6O2MW 194.15 Purity: 100% Soluble in 0.1N HCl(aq) and DMSO Description Chemotherapeutic apoptosis inducer. An orally active alkylating agent prodrug, delivering a methyl group to purine bases of DNA (O6-guanine; N7-guanine and N3-adenine). Temozolomide has demonstrated efficacy in the treatment of a variety of solid tumors, primary malignant brain tumors and metastatic melanoma (IC50 value 5 μM for cytotoxicity against mouse TLX5 lymphoma cells).The primary cytotoxic lesion, O6-methylguanine (O6-MeG) can be removed by methylguanine methyltransferase (MGMT; direct repair) in tumours expressing this protein, or tolerated in mismatch repair-deficient (MMR-) tumours. References Certificates Categories Extra info J. Zhang et al. Temozolomide: mechanisms of action, repair and resistance. Curr. Mol. Pharmacol. 2012, 5, 102-114.   H.S. Friedman et al. Temozolomide and treatment of malignant glioma. Clin. Cancer Res. 2000, 6, 2585-2597. Certificate of Analysis Material Safety Data Sheet Apoptosis Cell Cycle Regulation Cell Signaling & Oncology DNA-damage Response DNA DNA methylating agent; apoptosis inducer Chemical name 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide Parent CAS No. [85622-93-1] Order Size Unit Price Stock 10 mg €50.00 In Stockaxonmedchem
UCB-L 060 - Etiracetam, R-(+)-Axon 1111 CAS [103765-01-1] MF C8H14N2O2MW 170.21 Purity: 99% Optical purity: 98% ee Soluble in DMSO Description Acetylcholine agonist; less active enantiomer of Etiracetam (Axon 1109), in comparison with (S)-(-)-enantiomer, Levetiracetam (Axon 1110) References Certificates Categories Extra info Hovinga CA: Levetiracetam: a novel antiepileptic drug. Pharmacotherapy 2001, 21(11), 1375-1388. Certificate of Analysis Material Safety Data Sheet CNS SV2A Unclassified Least active enantiomer of Axon 1109 Chemical name (R)-2-(2-Oxo-pyrrolidin-1-yl)-butyramide Parent CAS No. [103765-01-1] Order Size Unit Price Stock 10 mg €85.00 In Stockaxonmedchem
LY 573636 - TasisulamAxon 1963 CAS [519055-62-0] MF C11H6BrCl2NO3S2MW 415.11 Purity: 98% Soluble in DMSO Description Anti-tumor agent, which causes growth arrest and apoptosis of a variety of human solid tumors in vitro and in vivo; LY573636 is selectively toxic towards tumor cells over their normal counterparts References Certificates Categories Extra info T Haritunians et al. Novel acyl sulfonamide LY573636-sodium: effect on hematopoietic malignant cells. Oncol Rep. 2008, 20(5), 1237-1242.      JM Kirkwood et al. A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma. Cancer 2011, 117(20), 4732–4739.  Certificate of Analysis Material Safety Data Sheet Angiogenesis Apoptosis Cell Cycle Regulation Cell Signaling & Oncology VEGFR RTK class IV; EC 2.7.10.1 Anti-tumor agent; causes growth arrest and apoptosis Chemical name N-(5-bromothiophen-2-ylsulfonyl)-2,4-dichlorobenzamide Parent CAS No. [519055-62-0] Order Size Unit Price Stock 10 mg €95.00 In Stockaxonmedchem
Dimethylcelecoxib, 2,5- - DMCAxon 2496 CAS [457639-26-8] MF C18H16F3N3O2SMW 395.40 Purity: 100% Soluble in DMSO Description Celecoxib analog that lacks COX-2 inhibitory activity but exhibits anti-tumor properties; DMC reduced growth and initiated apoptotic cell death in several MM cell lines. Mechanistically, DMC down-regulates critical components of the cell-cycle machinery (cyclins A and B); blocks the activity of important mitogenic and survival pathways (MEK, NF-κB, STAT3, survivin); and leads to increased caspase activity. Moreover, DMC quite potently mimics the ability of celecoxib to stimulate the endoplasmic reticulum stress response (ESR) and subsequent cell death . References Certificates Categories Extra info A. Kardosh et al. Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib. Blood. 2005 Dec 15;106(13):4330-8.   A. Kardosh et al. Dimethyl-celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-inhibitory function, potently mimics the anti-tumor effects of celecoxib on Burkitt's lymphoma in vitro and in vivo. Cancer Biol Ther. 2005 May;4(5):571-82.   P. Pyrko et al. Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib. Mol Cancer Ther. 2007 Apr;6(4):1262-75. Certificate of Analysis Material Safety Data Sheet Angiogenesis Cardiovascular Cell Cycle Regulation Cell Signaling & Oncology NF-κB MAPK JAK-STAT Unclassified Celecoxib analog with anti-tumor properties, lacking COX-2 inhibitory activity Chemical name 4-(5-(2,5-dimethylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide Parent CAS No. [457639-26-8] Order Size Unit Price Stock 10 mg €75.00 In Stockaxonmedchem
VU 0029767Axon 1988 CAS [326001-01-8] MF C21H21N3O3MW 363.41 Purity: 98% Soluble in DMSO Description Positive allosteric modulator of M1. VU 0029767 potentiates the agonistic effect of ACh for M1 (Ki value shifted by VU0029767 (3, 10 and 30 M) and shifted the ACh competition curve by 1.7 0.8-, 4.9 2.0-, and 8.8 1.9-fold, respectively, compared to control (DMSO; Ki value 8.7 µM). VU0029767 potentiates ACh-mediated intracellular calcium mobilization, but not phospholipase D activation. References Certificates Categories Extra info J.E. Marlo et al. Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity. Mol Pharmacol. 2009 Mar;75(3):577-88.   P.J. Conn et al. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol Sci. 2009 Mar;30(3):148-55. Certificate of Analysis Material Safety Data Sheet CNS CHRM1 A18 PAM of mAChR M1 that potentiates the agonistic effect of Ach Chemical name (E)-2-(4-ethoxyphenylamino)-N'-((2-hydroxynaphthalen-1-yl)methylene)acetohydrazide Parent CAS No. [326001-01-8] Order Size Unit Price Stock 10 mg €120.00 In Stockaxonmedchem
BMS 605541Axon 2837 CAS [639858-32-5] MF C19H17F2N5OSMW 401.43 Purity: 98% Soluble in DMSO Recently addedaxonmedchem
NVP-ACC789 - ACC789 | ZK 202650Axon 2865 CAS [300842-64-2] MF C21H17BrN4MW 405.29 Purity: 99% Soluble in DMSO Description NVP-ACC789 is a VEGFR2 inhibitor (IC50 value of 0.02 µM) moderately active against VEGFR1 and VEGFR3, but has little activity against PDGFR-β tyrosine kinases. Blocks angiogenesis induced by VEGF in vivo and in vitro. KEYWORDS: NVP-ACC789 | supplier | VEGFR2 inhibitor  | ACC789 | ZK 202650 | ACC-789 | ACC 789 | ZK-202650 | ZK202650 | CAS [300842-64-2] | VEGF | VEGFR | Inhibitor | Receptors | Angiogenesisaxonmedchem
Stem Cell 5i inhibitor SetAxon 5007 CAS [N.A.] MF #N/AMW #N/A Purity: 99% Soluble in DMSO Description A convenient set of five small molecule pathway inhibitors, BMP inhibitor LDN 193189 hydrochloride (Axon 1509), TGF-beta inhibitor SB 431542 (Axon 1661) and GSK3 inhibitor CHIR 99021 (Axon 1386), FGFR inhibitor SU 5402 (Axon 1667) and Gamma secretase inhibitor DAPT (Axon 1484) (termed as stem cell 5i or LSB3i or LSB+3i inhibitor set), for neural differentiation of human pluripotent stem cells (hPSCs). Stem Cell 5i (or LSB3i) inhibitor cocktail protocol, actually a combination of LSB inhibitor set (Axon 5004) and neuronal 3i (CSD) inhibitor set (Axon 5006), was used for rapid and efficient differentiateing hPSCs into nociceptors. Read more: Additional Product Information Show all Axon Ligand™ Sets References Certificates Categories Extra info S.M. Chambers et al. Combined small-molecule inhibition accelerates developmental timing and converts human pluripotent stem cells into nociceptors. Nature Biotechnol. 2012, 30, 715-720.   List of publications using LDN 193189 hydrochloride (Axon 1509) purchased from Axon Medchem  List of publications using CHIR 99021 (Axon 1386) purchased from Axon Medchem Certificate of Analysis Material Safety Data Sheet Additional Product Information Angiogenesis Apoptosis Cell Signaling & Oncology CNS Diabetes & Metabolism Immunology Pain & Inflammation Stem Cell VEGFR GSK-3 mTOR γ Secretase Wnt-β-Catenin TGF-β PI3K-Akt-mTOR Stem Cells Stem Cell Differentiator BMP-ALK FGFR TGF-βR Set of five inhibitors for neural differentiation of human pluripotent stem cells. Chemical name N.A. Parent CAS No. [N.A.] Order Size Unit Price Stock Each 2 mg €220.00 In Stockaxonmedchem
J147Axon 2859 CAS [1146963-51-0] MF C18H17F3N2O2MW 350.33 Purity: 100% Soluble in DMSO Description J147 is a potent and orally active neurotrophic drug that facilitates memory in normal rodents. Moreover, J147 prevents the loss of synaptic proteins and cognitive decline in a transgenic AD mouse model. Neuroprotectant. KEYWORDS: J147 | supplier | Neurotrophic drug | J 147 | J-147 | CAS [1146963-51-0] | Metabolism | Neuroprotectants | Alzheimer | Cognitive Enhancement | Neurodegenerativeaxonmedchem
Stem Cell CSD inhibitor SetAxon 5006 CAS [N.A.] MF #N/AMW #N/A Purity: 99% Soluble in DMSO Description A convenient set of three small molecule inhibitors, GSK-3 inhibitor CHIR 99021 (Axon 1386), FGFR inhibitor SU 5402 (Axon 1667) and gamma secretase inhibitor DAPT (Axon 1484) (termed as CSD or neuronal 3i). CHIR 99021 is the key factor for inducing neuronal differentiation, whereas SU 5402 and DAPT further enhance efficiency. Combination of stem cell CSD (neuronal 3i) inhibitor set with LSB inhibitor set (Axon 5004) forms stem cell 5i inhibitor set (Axon 5007, aka LSB3i or LSB+3i), which was used for rapid and efficient differentiation of human pluripotent stem cells (hPSCs) into nociceptors. Read more: Additional Product Information Show all Axon Ligand™ Sets References Certificates Categories Extra info S.M. Chambers et al. Combined small-molecule inhibition accelerates developmental timing and converts human pluripotent stem cells into nociceptors. Nature Biotechnol. 2012, 30, 715-720.   List of publications using CHIR 99021 (Axon 1386) purchased from Axon Medchem Certificate of Analysis Material Safety Data Sheet Additional Product Information Angiogenesis Cell Signaling & Oncology CNS Diabetes & Metabolism Immunology Pain & Inflammation Stem Cell VEGFR GSK-3 γ Secretase Wnt-β-Catenin PI3K-Akt-mTOR Stem Cells Stem Cell Differentiator FGFR Set of CHIR 99021, SU5402, and DAPT, inhibitors of GSK-3, FGFR, and γ-secretase, resp. Chemical name N.A. Parent CAS No. [N.A.] Order Size Unit Price Stock Each 2 mg €155.00 In Stockaxonmedchem
XL 388Axon 2951 CAS [1251156-08-7] MF C23H22FN3O4SMW 455.50 Purity: 99% Soluble in 0.1N HCl(aq) and DMSO Recently addedaxonmedchem
SUVN-502Axon 2715 CAS [1791396-46-7] MF C23H32BrN3O9S3MW 670.61 Purity: 99% Soluble in water and DMSO Description SUVN-502 is a potent, selective and orally active serotonin 6 (5-HT6) receptor antagonist (Ki value of 2.04 nM) with selectivity over 100 target sites which include receptors, enzymes, peptides, growth factors, ion channels, steroids, immunological factors, second messengers, and prostaglandins. Moreover, it has high selectivity over 5-HT2A receptor. SUVN-502 is brain penetrant and a clinical candidate for potential treatment of cognitive disorders. KEYWORDS: SUVN-502 | supplier | 5-HT6 antagonist | SUVN502 | SUVN 502 | CAS [1791396-46-7] | [701205-60-9] | Serotonin | 5-HT6 | Antagonist | Receptors | Alzheimeraxonmedchem
S-Propargyl-Cysteine - SPRC | ZYZ-802Axon 2666 CAS [3262-64-4] MF C6H9NO2SMW 159.21 Purity: 98% Optical purity: Optically pure Soluble in water Description S-Propargyl-cysteine (SPRC), a substrate of cystathionine γ-lyase (CSE), is a water-soluble modulator of endogenous hydrogen disulfide (H2S). SPRC is a potential agent for the treatment of Alzheimer’s disease (TNF signalling, the NF-κB pathway and the ERK1/2 pathway), anemia of inflammation (IL-6/JAK2/STAT3 pathway), ischemic heart disease (H2S/VEGFR2/STAT3 pathway) and myocardial infarction. KEYWORDS: S-Propargyl-Cysteine | supplier | H2S donor | SPRC | ZYZ-802 | S-Propargylcysteine | ZYZ802 | ZYZ 802 | CAS [3262-64-4] | L-cysteine | CSE | Activator | Enzymesaxonmedchem
eCF309Axon 2630 CAS [2001571-40-8] MF C18H21N7O3MW 383.40 Purity: 98% Moderately soluble in DMSO Description Potent inhibitor of mTOR signalling (IC50 value 10 - 15 nM in vitro and in vivo) with very high selectivity over other kinases, including PI3Ks. The selectivity profile of eCF309 is as good as or even better than that of any other selective mTOR inhibitor reported to date, making it a highly valuable probe for chemical biology and biomedicine. Note:axonmedchem
Lu AE58054 hydrochloride - Idalopirdine HClAxon 2144 CAS [467458-02-2] MF C20H19F5N2O.HClMW 434.83 Purity: 100% Soluble in water and DMSO Description 5-HT6 receptor antagonist (Ki value 0.83 nM for h5-HT6) demonstrating >50-fold selectivity for more than 70 targets examined, with good oral bioavailability and robust efficacy in a rat model of cognitive impairment in schizophrenia. Idalopirdine (Lu AE58054) potentiates the effects of Donepezil (Axon 1438) on two pharmacodynamic biomarkers associated with cognition, i.e. neuronal oscillations and extracellular ACh levels in the hippocampus. Noteaxonmedchem
5-HT6 antagonist 29Axon 1575 CAS [497963-70-9] MF C19H20ClN3O2S.HClMW 426.36 Purity: 99% Soluble in DMSO Description Selective brain penetrant 5-HT6 receptor antagonist (pKi value 8.6). Close regio-isomer of SB 699929 with brain–blood ratio of 2.6:1 and ED50 value of 5 mg/kg (po), and thus twice as potent as SB 271046 (Axon 1099). References Certificates Categories Extra info M. Ahmed et al. Bicyclic heteroarylpiperazines as selective brain penetrant 5-HT6 receptor antagonists. Bioorg. Med. Chem. Lett. 2005, 15, 4867-4871. Certificate of Analysis Material Safety Data Sheet CNS 5-HT6 A17 Selective brain penetrant 5-HT6 receptor antagonist Chemical name 3-(4-chlorophenylsulfonyl)-1-methyl-7-(piperazin-1-yl)-1H-indole hydrochloride Parent CAS No. [478082-77-8] Order Size Unit Price Stock 5 mg €90.00 In Stockaxonmedchem
SGS 518Axon 1927 CAS [445441-26-9] MF C21H22F2N2O3SMW 420.47 Purity: 99% Soluble in DMSO Description Selective 5-HT6 antagonist, being developed as a treatment for Cognitive Impairment Associated with Schizophrenia (CIAS) References Certificates Categories Extra info C Wilson, AV Terry. Enhancing cognition in neurologic disorders: Potential usefulness of 5-HT6 antagonists. Drugs Fut. 2009, 34(12), 969.    Certificate of Analysis Material Safety Data Sheet CNS 5-HT6 A17 Selective 5-HT6 antagonist Chemical name 1-methyl-3-(1-methylpiperidin-4-yl)-1H-indol-5-yl 2,6-difluorobenzenesulfonate Parent CAS No. [445441-26-9] Order Size Unit Price Stock 5 mg €90.00 In Stockaxonmedchem
MS 245 oxalateAxon 1849 CAS [275363-58-1] MF C19H22N2O3S.C2H2O4MW 448.49 Purity: 99% Soluble in DMSO Description Selective and high affinity 5-HT6 antagonist (Ki = 2.1 nM) References Certificates Categories Extra info Y Tsai et al. N1-(Benzenesulfonyl)tryptamines as novel 5-HT6 antagonists. Bioorg Med Chem Lett. 2000, 10(20), 2295-2299.   R Young et al. Effect of the 5-HT(6) serotonin antagonist MS-245 on the actions of (-)nicotine. Pharmacol. Biochem. Behav. 2006, 85(1), 170-1777.    M Dukat et al. Binding of serotonin and N1-benzenesulfonyltryptamine-related analogs at human 5-HT6 serotonin receptors: receptor modeling studies. J. Med. Chem. 2008, 51, 603.    RVS Nirogi et al. Novel and potent 5-piperazinyl methyl-N1-aryl sulfonyl indole derivatives as 5-HT6 receptor ligands. ACS Med. Chem. Lett. 2010, 1, 340. Certificate of Analysis Material Safety Data Sheet CNS 5-HT6 A17 5-HT6 antagonist Chemical name 2-(5-methoxy-1-(phenylsulfonyl)-1H-indol-3-yl)-N,N-dimethylethanamine oxalate Parent CAS No. [263384-65-2] Order Size Unit Price Stock 10 mg €105.00 In Stockaxonmedchem
WAY 208466 dihydrochlorideAxon 1710 CAS [1207064-61-6] MF C17H18FN3O2S.2HClMW 420.33 Purity: 99% Soluble in water Description Potent and highly selective serotonin 5-HT6 receptor agonist (EC50: 7.3 nM); increases GABA levels in the cerebral cortex; produces antidepressant and anxiolytic effects in rodents; useful in the treatment of obsessive-compulsive disorder (OCD) References Certificates Categories Extra info LE Schechter et al. Neuropharmacological Profile of Novel and Selective 5-HT6 Receptor Agonists: WAY-181187 and WAY-208466. Neuropsychopharmacology 2008, 33, 1323–1335.   GV Carr et al. Antidepressant and anxiolytic effects of selective 5-HT(6) receptor agonists in rats. Psychopharmacology 2010, 213(2–3), 499–507. Certificate of Analysis Material Safety Data Sheet CNS 5-HT6 A17 Potent and selective 5-HT6 receptor agonist Chemical name 2-(3-(3-fluorophenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-1-yl)-N,N-dimethylethanamine dihydrochloride Parent CAS No. [633304-27-5] Order Size Unit Price Stock 10 mg €120.00 In Stockaxonmedchem
RO 04-6790 hydrochlorideAxon 1330 CAS [1197333-95-1] MF C12H16N6O2S.2HClMW 381.28 Purity: 98% Soluble in 0.1N HCl(aq) Description Potent and selective serotonin 5-HT6 receptor antagonist References Certificates Categories Extra info AJ Sleight et al. Characterization of Ro 04-6790 and Ro 63-0563: Potent and selective antagonists at human and rat 5-HT6 receptors. Br. J. Pharmacol. 1998, 124, 556-562.   JC Bentley et al. Investigation of stretching behavior induced by the selective 5-HT6 receptor antagonist Ro 04-6790 in rats. Br. J. Pharmacol. 1999, 126, 1537-1542.   Lindner, M.D. et al. An assessment of the effects of serotonin 6 (5-HT6) Receptor antagonists in rodent models of learning. J. Pharmacol. Exp. Ther. 2003, 307(2), 682-691. Certificate of Analysis Material Safety Data Sheet CNS 5-HT6 A17 5-HT6 antagonist Chemical name 4-Amino-N-(2,6-bis-methylamino-pyrimidin-4-yl)-benzenesulfonamide hydrocholoride Parent CAS No. [202466-68-0] Order Size Unit Price Stock 10 mg €95.00 In Stockaxonmedchem
Olanzapine - LY 170053Axon 1298 CAS [132539-06-1] MF C17H20N4SMW 312.43 Purity: 99% Soluble in DMSO Description Atypical antipsychotic; Higher affinity for 5-HT2 receptors than D2 receptors. D1/D2/D4/5-HT2C antagonist. Also nanomolar affinity for 5-HT6/5-HT7 receptors. Weak activity on dopamine sites, appears to bind to M3 and M4 receptor sites. Anticholinergic and anxiolytic properties References Certificates Categories Extra info Certificate of Analysis Material Safety Data Sheet CNS D2 5-HT6 5-HT7 5-HT2C 5-HT2 D4 CHRM3 D1 CHRM4 CHRM1 A17 Atypical antipsychotic Chemical name 2-Methyl-10-(4-methyl-piperazin-1-yl)-4H-3-thia-4,9-diaza-benzo[f]azulene Parent CAS No. [132539-06-1] Order Size Unit Price Stock 10 mg €75.00 In Stockaxonmedchem
SB 271046 hydrochlorideAxon 1099 CAS [209481-24-3] MF C20H22ClN3O3S2.HClMW 488.45 Purity: 99% Soluble in DMSO Description Putative 5-HT6 antagonist References Certificates Categories Extra info SM Bromidge et al. 5-Chloro-N-(4-methoxy-3-piperazin-1-yl- phenyl)-3-methyl-2-benzothiophenesulfon- amide (SB-271046): a potent, selective, and orally bioavailable 5-HT6 receptor antagonist. J. Med. Chem. 1999, 42(2), 202-5.   C Routledge et al. Characterization of SB-271046: a potent, selective and orally active 5-HT(6) receptor antagonist. Br. J. Pharmacol. 2000, 130(7), 1606-1612.   AG Foley et al. The 5-HT(6) receptor antagonist SB-271046 reverses scopolamine-disrupted consolidation of a passive avoidance task and ameliorates spatial task deficits in aged rats. Neuropsychopharmacol. 2004, 29(1), 93-100.  Certificate of Analysis Material Safety Data Sheet CNS 5-HT6 A17 5-HT6 antagonist Chemical name 5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonic acid (4-methoxy-3-piperazin-1-yl-phenyl)-amide hydrochloride Parent CAS No. [209481-20-9] Order Size Unit Price Stock 10 mg €95.00 In Stockaxonmedchem
VA012Axon 2889 CAS [885898-58-8] MF C21H19N3MW 313.40 Purity: 99% Soluble in DMSO Recently addedaxonmedchem
MHY 1485Axon 2425 CAS [326914-06-1] MF C17H21N7O4MW 387.39 Purity: 99% Soluble in DMSO Description mTOR activator with an inhibitory effect on autophagy. MHY1485 markedly increased the LC3II/LC3I ratio dose-dependently and time-dependently by inhibition of the fusion between autophagosomes and lysosomes, and without increasing the autophagic flux. At 2 µM, MHY1485 did not show any cell death during longer treatment, supporting that MHY1485 had less toxicity than other well-known inhibitors of autophagy. MHY1485 was also tested and found moderately active as antimalarial agent (MIC value of ca. 26 µM against P. Falciparum). References Certificates Categories Extra info Y.J. Choi et al. Inhibitory effect of mTOR activator MHY1485 on autophagy: suppression of lysosomal fusion. PLoS One. 2012;7(8):e43418.   A. Agarwal et al. Syntheses of 2,4,6-trisubstituted triazines as antimalarial agents. Bioorg Med Chem Lett. 2005 Feb 1;15(3):531-3.   H. Ojha et al. Quantitative structure activity relationship study of 2,4,6-trisubstituted-s-triazine derivatives as antimalarial inhibitors of Plasmodium falciparum dihydrofolate reductase. Chem Biol Drug Des. 2011 Jan;77(1):57-62. Certificate of Analysis Material Safety Data Sheet Angiogenesis Cell Signaling & Oncology Immunology mTOR PI3K-Akt-mTOR EC 2.7.11.1 Antiprotozoal agents Autophagy mTOR activator with an inhibitory effect on autophagy Chemical name 4,6-dimorpholino-N-(4-nitrophenyl)-1,3,5-triazin-2-amine Parent CAS No. [326914-06-1] Order Size Unit Price Stock 10 mg €70.00 In Stockaxonmedchem
Bifeprunox mesylate - DU 127090Axon 1508 CAS [350992-13-1] MF C24H23N3O2.CH4O3SMW 481.56 Purity: 98% Soluble in DMSO Description Dopamine D2 and 5-HT1A partial agonist in development as a potential treatment for schizophrenia and other psychotic indications; Pharmacoloy profile makes it an atypical antipsychotic and a new approach for the treatment of schizophrenia. KEYWORDS: Bifeprunox mesylate | Supplier | D2/5-HT1A agonist | DU 127090 | DU127090 | DU-127090 | CAS [350992-13-1] | [350992-10-8] | Serotonin | Dopamine | D2 | 5-HT1A | schizophrenia | psychotic indications | atypical | antipsychotic | extrapyramidal symptomsaxonmedchem
WAY 100635 maleateAxon 2424 CAS [1092679-51-0] MF C25H34N4O2.C4H4O4MW 538.64 Purity: 98% Soluble in water and DMSO Description Prototypical 5-HT1A receptor antagonist with D4 agonist activity (Ki values 2.2 nM, 6260 nM, 24 nM, >10,000 nM, 20 nM, 322 nM, and 16 nM for 5-HT1A, 5-HT2A, 5-HT2B, 5-HT7, α1A, α1B, and D4, respectively). The HCl salt of WAY 100635 is available as well (Axon 1086) References Certificates Categories Extra info B.R. Chemel et al. WAY-100635 is a potent dopamine D4 receptor agonist. Psychopharmacology (Berl). 2006 Oct;188(2):244-51.   EA Forster et al. A pharmacological profile of the selective silent 5-HT1A receptor antagonist WAY-100635. Eur. J. Pharmacol. 1995, 281, 81-88.    F. Mangin et al. Moderate chemical modifications of WAY-100635 improve the selectivity for 5-HT1A versus D4 receptors. Bioorg Med Chem Lett. 2012 Jul 15;22(14):4550-4. Certificate of Analysis Material Safety Data Sheet Cell Signaling & Oncology CNS 5-HT1A D4 Adrenoceptor α1 A19 5-HT1A antagonist with D4 agonistic properties Chemical name Cyclohexanecarboxylic acid {2-[4-(2-methoxy-phenyl)-piperazin-1-yl]-ethyl}-pyridin-2-yl-amide maleate Parent CAS No. [162760-96-5] Order Size Unit Price Stock 10 mg €125.00 In Stockaxonmedchem
IITZ-01Axon 2933 CAS [1807988-47-1] MF C26H23FN8OMW 482.51 Purity: 99% Soluble in DMSO Recently addedaxonmedchem
MSL-7Axon 2932 CAS [2172949-70-9] MF C16H12ClNO4SMW 349.79 Purity: 99% Soluble in DMSO Recently addedaxonmedchem
A 381393Axon 2944 CAS [726174-00-1] MF C20H24N4MW 320.43 Purity: 99% Soluble in 0.1N HCl(aq) and DMSO Recently addedaxonmedchem
QX77Axon 2902 CAS [1798331-92-6] MF C16H13ClN2O2MW 300.74 Purity: 98% Soluble in DMSO Description Chaperone-mediated autophagy (CMA) activator. QX77 operates through the release of the endogenous inhibition of the retinoic receptor-α signaling pathway over the regulation of multiple mechanisms that modulate CMA. KEYWORDS: QX77 | supplier | CMA activator | QX 77 | QX-77 | CAS [1798331-92-6] | Retinoic Acid |  Retinoic Acid (RAR)  | Antagonist | Receptors | Cystinosis | LAMP2A | Cystinosinaxonmedchem
Sonepiprazole hydrochloride - PNU 101387Axon 2115 CAS [170857-36-0] MF C21H27N3O3S.HClMW 437.98 Purity: 98% Optical purity: Optically pure Soluble in DMSO Description Selective dopamine D4 antagonist; Displayed high affinity (Ki = 10 nM) and selectivity for the D4 receptor expressed in clonal cell lines, lacking measurable affinity for other dopamine receptors, and noradrenalin, serotonin and histamine receptor families (Ki > 2000 nM) References Certificates Categories Extra info PA Broderick et al. Clozapine, haloperidol, and the D4 antagonist PNU-101387G: in vivo effects on mesocortical, mesolimbic, and nigrostriatal dopamine and serotonin release. J. Neural. Transm. 1998, 105(6-7), 749-767.    KM Merchant et al. Pharmacological characterization of U-101387, a dopamine D4 receptor selective antagonist. J. Pharmacol. Exp. Ther. 1996, 279(3), 1392-1403.  Certificate of Analysis Material Safety Data Sheet CNS D4 A17 Pfizer Licensed Products Selective dopamine D4 antagonist Chemical name (S)-4-(4-(2-(isochroman-1-yl)ethyl)piperazin-1-yl)benzenesulfonamide hydrochloride Source information Pfizer compound; Sold for research purposes under agreement from Pfizer Inc. Parent CAS No. [170858-33-0] Order Size Unit Price Stock 5 mg €85.00 In Stockaxonmedchem
STF 62247Axon 2894 CAS [315702-99-9] MF C15H13N3SMW 267.35 Purity: 99% Soluble in DMSO Description STF 62247 selectively targets VHL-deficient renal cell carcinoma (RCC) cells (IC50 value of 0.625 µM in RCC4). STF 62247-stimulated toxicity occurs in a HIF-independent manner through autophagy. Moreover, STF 62247 induced apoptotic and autophagic cell death in leukemic cells. Keywords: STF 62247 | supplier | Inducer of apoptosis and autophagy | STF-62247 | STF62247 | CAS [315702-99-9] | Smad | Ubiquitin Ligase (E3; VHL) | Inducer | Enzymes | VHL | RCC | Leukemia | ATL | HTLV-1axonmedchem
LY 2955303 dihydrochlorideAxon 2637 CAS [N.A.] MF C36H42N4O3.2HClMW 651.67 Purity: 99% Soluble in DMSO Description Potent and selective retinoic acid receptor gamma (RARγ) antagonist (Ki values >1700 nM, >2980 nM, and 1.1 nM for RARα, RARβ, and RARγ, respectively) for the treatment of osteoarthritis joint pain. KEYWORDS: LY 2955303 dihydrochloride | supplier | RARγ antagonist | LY2955303 diHCl | LY-2955303 dihydrochloride | CAS [N.A.] | [1433497-19-8] | Retinoic Acid | Retinoic Acid (RAR) | Nuclear receptors | NR1B | osteoarthritis | pain | Antagonist | Receptorsaxonmedchem
JTP 0819958 - HOIPIN-1Axon 2939 CAS [N.A.] MF C17H13NaO4MW 304.27 Purity: 99% Soluble in water and DMSO Recently addedaxonmedchem
UNC 9994 hydrochlorideAxon 2562 CAS [N.A.] MF C21H22Cl2N2OS.HClMW 457.84 Purity: 99% Soluble in DMSO Description Unique, β-arrestin-biased functionally selective dopamine D2 receptor (D2R) agonist (Ki value 30 nM; EC50 value 50 nM in β-arrestin-2 recruitment assay) that exhibits antipsychotic activity in vivo. UNC9994 markedly inhibited PCP-induced hyperlocomotion in wild-type mice, which effect was completely abolished in β-arrestin-2 knockout mice. KEYWORDS: UNC 9994 hydrochloride | supplier | D2 agonist | Axon Medchem | Axon 2562 | UNC9994 | CAS [1354030-51-5] | Dopamine | D2 | Agonist | GPCR | D2R | β-arrestin | beta-arrestin | antipsychoticaxonmedchem
NRX 194204 - IRX4204 | NRX 4204 | VTP 194204 | AGN 194204 | AGN 4204Axon 2408 CAS [220619-73-8] MF C24H32O2MW 352.51 Purity: 99% Optical purity: Optically pure Soluble in DMSO Description Highly potent and specific RXR agonist (Kd values 0.4 nM, 3.6 nM, and 3.8 nM for RXRα, RXRβ, and RXRγ, respectively) devoid of any RAR activity (Kd values >30 µM for RARα, RARβ, and RARγ). NRX 194204 blocked the ability of lipopolysaccharide and TNFα to induce the release of nitric oxide and IL6 and the degradation of IKBα in RAW264.7 macrophage-like cells. NRX194204 prevents carcinogenesis in both the lung and mammary gland, and enhances the ability of ligands for PPARs or cytotoxic drugs, including cisplatin and 5-flurouracil, to inhibit proliferation and induce apoptosis in breast and pancreatic cancer cell lines. KEYWORDS: NRX 194204 | RXR agonist | NRX 4204 | VTP 194204 | AGN 194204 | AGN 4204 | NRX4204;NRX-4204; IRX 4204; IRX-4204 | NRX194204; NRX-194204 | VTP194204; VTP-194204 | AGN194204; AGN-194204 | AGN4204; AGN-4204 | CAS [220619-73-8] | Retinoic Acid | Retinoic Acid (RXR) | devoid | RAR | carcinogenesis | Agonist | Receptorsaxonmedchem
SAR405838 - MI-77301Axon 2741 CAS [1303607-60-4] MF C29H34Cl2FN3O3MW 562.50 Purity: 98% Optical purity: Optically pure Soluble in DMSO Description SAR405838 is an inhibitor of the MDM2-p53 interaction with high specificity over other proteins (Ki value of 0.88 nM). SAR405838 effectively activates wild-type p53 in vitro and in xenograft tumor tissue of leukemia and solid tumors, leading to p53-dependent cell-cycle arrest and/or apoptosis. At well-tolerated dose schedules, SAR405838 achieves either durable tumor regression or complete tumor growth inhibition in mouse xenograft models of SJSA-1 osteosarcoma, RS4;11 acute leukemia, LNCaP prostate cancer, and HCT-116 colon cancer. KEYWORDS: SAR405838 | supplier | MDM2 inhibitor | MI-77301 | SAR 405838 | SAR-405838 | MI 77301 | MI77301 | CAS [1303607-60-4] | p53 | HDM-MDM | Inhibitor | Enzymes | Apoptosisaxonmedchem
NS 30678 hydrochlorideAxon 1742 CAS [1193707-19-5] MF C12H16ClNO4S.HClMW 342.24 Purity: 99% Optical purity: Optically pure Soluble in water and DMSO Description Dopamine D2 receptor ligand with surmountable/competitive-like D2 antagonist properties (Ki and IC50 values of value 9.7 nM and 7 nM, repectively in HEK-hD2L-Gαqi5 cells), equipotent to Haloperidol and Risperidone (Axon 1454). NS30678 shows rapid recovery and dopamine responsiveness within 5 min after administration. References Certificates Categories Extra info T. Dyhring et al. The dopaminergic stabilizers pridopidine (ACR16) and (-)-OSU6162 display dopamine D(2) receptor antagonism and fast receptor dissociation properties. Eur J Pharmacol. 2010 Feb 25;628(1-3):19-26.   K. Sahlholm et al. Typical and atypical antipsychotics do not differ markedly in their reversibility of antagonism of the dopamine D2 receptor. Int J Neuropsychopharmacol. 2014 Jan;17(1):149-55. Certificate of Analysis Material Safety Data Sheet CNS D2 A17 D2 ligand with surmountable/competitive-like D2 antagonist properties Chemical name (S)-N-((5-chloro-7-(methylsulfonyl)-2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)ethanamine hydrochloride Parent CAS No. [1193707-15-1] Order Size Unit Price Stock 2 mg €115.00 In Stockaxonmedchem
AMG 232Axon 2639 CAS [1352066-68-2] MF C28H35Cl2NO5SMW 568.55 Purity: 100% Optical purity: Optically pure Soluble in 0.1N NaOH(aq) and DMSO Description Potent, selective, and orally bioavailable MDM2-p53 inhibitor (IC50 value 9.1 nM, Kd 0.045 nM), demonstrating remarkable pharmacokinetic properties and in vivo antitumor activity in the SJSA-1 osteosarcoma xenograft model. Moreover, AMG 232 activates p53 pathway activity in vivo, and potentiates the activity of p53-inducing cytotoxic agents. KEYWORDS: AMG 232 | supplier | MDM2 inhibitor | AMG232 | AMG-232 | CAS [1352066-68-2] | Axon Medchem | Axon 2639 | p53 | HDM-MDM | orally bioavailable | MDM2-p53 interaction | antitumor activity | SJSA-1 | osteosarcoma | xenograft model | p21axonmedchem
N106Axon 2565 CAS [862974-25-2] MF C17H14N4O3SMW 354.38 Purity: 99% Soluble in DMSO Description First-in-class small-molecule activator targeting E1 ligase mediated SERCA2a SUMOylation. N106 treatment increases contractile properties of cultured rat cardiomyocytes and significantly improves ventricular function in mice with heart failure. KEYWORDS: N106 | supplier | E1 ligase activator | N-106 | CAS [862974-25-2] | Ubiquitin | Ubiquitin Ligase (E1) | Activator | small ubiquitin-like modifier type 1 | SUMO-1 | SERCA2a | SUMOylation | heart failure | cardiomyocyte | cardiac | sarcoplasmic reticulum | calcium | ATPaseaxonmedchem
JNJ 26854165 dihydrochloride - Serdemetan dihydrochlorideAxon 1586 CAS [881202-16-0] MF C21H20N4.2HClMW 401.33 Purity: 99% Soluble in water and DMSO Description Oral HDM2 inhibitor (or antagonist), which showed potent activity against multiple myeloma (MM) cells in vitro and ex vivo; potential agent to restore p53 function and to potentially impact other HDM2 dependent pathways. Note: JNJ 26854165 dihydrochloride is a directly water-soluble form of JNJ 26854165 (Axon 1538) KEYWORDS: JNJ26854165 dihydrochloride | Supplier | HDM2 inhibitor | Serdemetan dihydrochloride | JNJ26854165 | CAS [881202-16-0] | [881202-45-5] | p53 | HDM-MDM | Inhibitor | antagonist | multiple myeloma | MM | pathwaysaxonmedchem
CC-885Axon 2645 CAS [1010100-07-8] MF C22H21ClN4O4MW 440.88 Purity: 99% Soluble in DMSO Description Cereblon (CRBN) modulator with potent anti-tumour activity which is mediated through the cereblon-dependent ubiquitination and degradation of the translation termination factor GSPT1. CC-885 exhibits potent anti-proliferative activity in patient-derived acute myeloid leukaemia (AML) tumour cell lines. KEYWORDS: CC-885 | supplier | Cereblon (CRBN) modulator | CC885 | CAS [1010100-07-8] | Ubitquitin | signaling | E3 ligase | GSPT1 | CRL4 | DDB1 | CUL4 | AML | myeloid leukaemiaaxonmedchem
CDN1163Axon 2684 CAS [892711-75-0] MF C20H20N2O2MW 320.39 Purity: 100% Soluble in DMSO Description CDN1163 is an allosteric activator of sarco/endoplasmic reticulum Ca2+-ATPase 2b (SERCA2b) and markedly lowered fasting blood glucose, improved glucose tolerance, and ameliorated hepatosteatosis in a genetic model of insulin resistance and type 2 diabetes (ob/ob mice). CDN1163 treatment significantly reduced the hepatic expression of genes involved in gluconeogenesis and lipogenesis, attenuated ER stress response and ER stress-induced apoptosis, and improved mitochondrial biogenesis. Moreover, CDN1163 increased ER calcium content, rescued neurons from ER stress-induced cell death in vitro, and showed significant efficacy in the rat 6-hydroxydopamine (6-OHDA) model of Parkinson's disease. KEYWORDS: CDN1163 | supplier | SERCA activator | CDN 1163 | CDN-1163 | CAS [892711-75-0] | ATP | ATPase (Ca2+) | Activator | Enzymes | SERCA | 6-OHDA | Obesitas | Diabetes | Metabolic Disorder | Metabolic Dysfunction | ER Stress | Parkinson's Diseaseaxonmedchem
Tenovin 1Axon 2008 CAS [380315-80-0] MF C20H23N3O2SMW 369.48 Purity: 99% Soluble in DMSO Description p53 activator that has the potential to decrease tumor growth; Tenovin 1 acts through inhibition of the protein-deacetylating activities of SIRT1 and SIRT2, two important members of the sirtuin family References Certificates Categories Extra info S Lain et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell. 2008, 13(5), 454-463.  Certificate of Analysis Material Safety Data Sheet Apoptosis Cell Cycle Regulation Cell Signaling & Oncology CNS Diabetes & Metabolism Epigenetics DNA-damage Response EC 3.5.1.98 SIRT Activates p53 through inhibition of SIRT 1 and 2 Chemical name N-(4-acetamidophenylcarbamothioyl)-4-tert-butylbenzamide Parent CAS No. [380315-80-0] Order Size Unit Price Stock 10 mg €70.00 In Stockaxonmedchem
LDN 57444Axon 2449 CAS [668467-91-2] MF C17H11Cl3N2O3MW 397.64 Purity: 99% Soluble in DMSO Description Reversible, competitive inhibitor of UCH-L1 (Ki value 0.40 µM; IC50 values 0.88 µM and 25 µM for UCH-L1 and UCH-L3 inhibition, respectively), that promotes proliferation of H1299 NSCLC cells and SH-SY5Y neuroblastoma cells. A usefull tool to study the role of UCH-L1 in Parkinson’s disease, cancer, and neuropathic pain. References Certificates Categories Extra info Y. Liu et al. Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. Chem Biol. 2003 Sep;10(9):837-46.   UCH-L1 inhibition involved in CREB dephosphorylation in hippocampal slices. M Xie et al. J Mol Neurosci. 2014 May;53(1):59-68. Certificate of Analysis Material Safety Data Sheet Apoptosis Cell Cycle Regulation Cell Signaling & Oncology CNS Pain & Inflammation Ubiquitin EC 3.4.19.12 Deubiquitinase Reversible, competitive inhibitor of UCH-L1 deubiquitinase Chemical name 3-(acetoxyimino)-5-chloro-1-(2,5-dichlorobenzyl)indolin-2-one Parent CAS No. [668467-91-2] Order Size Unit Price Stock 10 mg €95.00 In Stockaxonmedchem
OSS-128167Axon 2843 CAS [887686-02-4] MF C19H14N2O6MW 366.32 Purity: 99% Soluble in 0.1N NaOH(aq) and DMSO Description OSS-128167 is a selective SIRT6 inhibitor (IC50 value of 89 µM). KEYWORDS: OSS-128167 | supplier | SIRT 6 inhibitor | OSS128167 | OSS 128167 | CAS [887686-02-4] | Histone | SIRT | Inhibitor | Enzymes | Sirtuin | Diabetesaxonmedchem
TCIDAxon 2333 CAS [30675-13-9] MF C9H2Cl4O2MW 283.92 Purity: 99% Soluble in DMSO Description Potent, cell permeant inhibitor of UCHL3 (IC50 value 0.6 µM) with 125-fold selectivity over UCHL1. Specific inhibition of UCHL3 with TCID diminished GlyT2 ubiquitination in brainstem and spinal cord primary neurons and may be beneficial in several human disorders, including neuromotor deficiencies (startle disease, myoclonus), pain and epilepsy. References Certificates Categories Extra info Y. Liu et al. Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. Chem. Biol. 2003, 10, 837-846.   J. de Juan-Sanz et al. Constitutive endocytosis and turnover of the neuronal glycine transporter GlyT2 is dependent on ubiquitination of a C-terminal lysine cluster. PLoS One. 2013, 8, e58863. Certificate of Analysis Material Safety Data Sheet Apoptosis Cell Cycle Regulation Cell Signaling & Oncology Ubiquitin EC 3.4.19.12 Deubiquitinase Potent inhibitor of UCHL3 with >100-fold selectivity over UCHL1 Chemical name 4,5,6,7-tetrachloro-1H-indene-1,3(2H)-dione Parent CAS No. [30675-13-9] Order Size Unit Price Stock 10 mg €80.00 In Stockaxonmedchem
ML364Axon 2678 CAS [1991986-30-1] MF C24H18F3N3O3S2MW 517.54 Purity: 99% Soluble in DMSO Description ML364, a small molecule inhibitor of the deubiquitinase USP2 (IC50 value of 1.1 μM), induced an increase in cellular cyclin D1 degradation and caused cell cycle arrest. Consistent with the role of cyclin D1 in DNA damage response, ML364 also caused a decrease in homologous recombination-mediated DNA repair. These effects by a small molecule inhibitor support a key role for USP2 as a regulator of cell cycle, DNA repair, and tumor cell growth. KEYWORDS: ML364 | supplier | USP2 inhibitor | ML 364 | ML-364 | CAS [1991986-30-1] | Non Selective (Ubiquitin peptides) | Deubiquitinase | Inhibitor | Enzymesaxonmedchem
ONX 0914 - PR 957Axon 2199 CAS [960374-59-8] MF C31H40N4O7MW 580.67 Purity: 98% Optical purity: Optically pure Soluble in 0.1N HCl(aq) and DMSO Description Selective inhibitor of LMP7, the chymotrypsin-like subunit of the immunoproteasome. ONX 0914 blocks the production of cytokines IL-23, TNF-α, and IL-6 in a NF-κB independent manner, and attenuates progression of experimental arthritis in mouse models.ONX 0914 induces an anti-inflammatory response at doses less than one tenth of the maximum tolerated dose, in contrast to nonselective inhibitors, such as bortezomib (Axon 1810) and carfilzomib. References Certificates Categories Extra info T. Muchamuel et al. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat. Med. 2009, 15, 781-788.    S.E. Verbrugge et al. Inactivating PSMB5 Mutations and P-Glycoprotein (Multidrug Resistance-Associated Protein/ATP-Binding Cassette B1) Mediate Resistance to Proteasome Inhibitors: Ex Vivo Efficacy of (...). J. Pharmacol. Exp. Ther. 2012, 341, 174-182.  Certificate of Analysis Material Safety Data Sheet Cell Signaling & Oncology Immunology Pain & Inflammation Immunomodulator Proteasome 26S Ubiquitin EC 3.4 Selective inhibitor of LMP7 subunit of the immunoproteasome. Chemical name (S)-3-(4-methoxyphenyl)-N-((S)-1-((R)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propanamide Parent CAS No. [960374-59-8] Order Size Unit Price Stock 2 mg €95.00 In Stockaxonmedchem
Bortezomib - PS 341Axon 1810 CAS [179324-69-7] MF C19H25BN4O4MW 384.24 Purity: 99% Optical purity: Optically pure Soluble in DMSO Description Highly selective and reversible inhibitor of the 26S proteasome; a chemotherapy agent used in the treatment of multiple myeloma; shown to have anti-tumor activity in B cell malignancies References Certificates Categories Extra info P Bonvini et al. Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma. Leukemia 2007, 21(4), 838–842.   S Williams et al. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol. Cancer Ther. 2003, 2, 835-843.   Y Ling et al. Mechanisms of Proteasome Inhibitor PS-341-induced G2-M-Phase Arrest and Apoptosis in Human Non-Small Cell Lung Cancer Cell Lines. Clin. Cancer Res. 2003, 9, 1145-1154.   A Corso et al. Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma. Leukemia & Lymphoma 2010, 51(2), 236-242. Certificate of Analysis Material Safety Data Sheet Cell Signaling & Oncology Proteasome 26S Ubiquitin EC 3.4 Inhibitor of 26S proteasome Chemical name (R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butan-2-ylboronic acid Parent CAS No. [179324-69-7] Order Size Unit Price Stock 5 mg €85.00 In Stockaxonmedchem
 1 2 3 4 5 6 7 8 9 > >| 第 1/34 页